Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis

Jamie R. Felzer, Delvise T. Fogwe, Shaher Samrah, Clement J. Michet, Ulrich Specks, Misbah Baqir, Aahd F. Kubbara

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Inflammatory processes, such as an infection or drug reaction, can cause antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). Although quite rare, AAV may occur with SARS-coronavirus disease 2019 (COVID-19) antigenic exposure, either from infection or immunization. We present two cases of AAV: one that developed after COVID-19 infection presenting as diffuse alveolar haemorrhage and another that developed shortly after vaccination, presenting as granulomatous pulmonary nodules. Both patients improved with supportive care and immunosuppressive therapies. This adverse event appears to be a very rare complication of COVID-19 infection or vaccination. Early diagnosis of AAV is important because immunosuppressive therapy may improve patient outcomes.

Original languageEnglish (US)
Article numbere0894
JournalRespirology Case Reports
Volume10
Issue number1
DOIs
StatePublished - Jan 2022

Bibliographical note

Funding Information:
Marianne Mallia, ELS, MWC, Senior Scientific/Medical Editor, Mayo Clinic, substantively edited the manuscript. The Scientific Publications staff at Mayo Clinic provided proofreading, administrative, and clerical support.

Publisher Copyright:
© 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.

Fingerprint

Dive into the research topics of 'Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis'. Together they form a unique fingerprint.

Cite this